$0.829000
-0.01-1.19%
Last update: Jul 24, 8:15 AM
15 minutes delayed
Comments
Loading...
Achilles Therapeutics
ACHLNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Achilles Therapeutics (NASDAQ:ACHL) Stock, Analyst Ratings, Price Targets, Forecasts
Achilles Therapeutics PLC has a consensus price target of $2.83 based on the ratings of 3 analysts. The high is $6 issued by Chardan Capital on April 5, 2024. The low is $0.5 issued by B of A Securities on December 14, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Chardan Capital, and B of A Securities on April 5, 2024, April 5, 2024, and December 14, 2023, respectively. With an average price target of $2.83 between Piper Sandler, Chardan Capital, and B of A Securities, there's an implied 237.38% upside for Achilles Therapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Chardan Capital
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Achilles Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | Buy Now | 138.15% | Piper Sandler | Joseph Catanzaro | $8 → $2 | Downgrade | Overweight → Neutral | Get Alert |
| 04/05/2024 | Buy Now | 614.46% | Chardan Capital | Geulah Livshits | $11 → $6 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | -40.46% | B of A Securities | Tazeen Ahmad | $7 → $0.5 | Downgrade | Buy → Underperform | Get Alert |
| 08/07/2023 | Buy Now | 1209.84% | Chardan Capital | Geulah Livshits | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 1209.84% | Chardan Capital | Geulah Livshits | $12 → $11 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 1924.29% | Chardan Capital | Geulah Livshits | $20 → $17 | Maintains | Buy | Get Alert |
| 12/07/2022 | Buy Now | 852.61% | Piper Sandler | Joseph Catanzaro | $10 → $8 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Achilles Therapeutics (ACHL) stock?
The latest price target for Achilles Therapeutics (NASDAQ:ACHL) was reported by Piper Sandler on April 5, 2024. The analyst firm set a price target for $2.00 expecting ACHL to rise to within 12 months (a possible 141.25% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
The latest analyst rating for Achilles Therapeutics (NASDAQ:ACHL) was provided by Piper Sandler, and Achilles Therapeutics downgraded their neutral rating.
When was the last upgrade for Achilles Therapeutics (ACHL)?
There is no last upgrade for Achilles Therapeutics
When was the last downgrade for Achilles Therapeutics (ACHL)?
The last downgrade for Achilles Therapeutics PLC happened on April 5, 2024 when Piper Sandler changed their price target from $8 to $2 for Achilles Therapeutics PLC.
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a downgraded with a price target of $8.00 to $2.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.